Alnylam Pharmaceuticals Stock Rises as FDA Lifts Study Hold
15 Dezembro 2017 - 11:01AM
Dow Jones News
Alnylam Pharmaceuticals Inc.'s (ALNY) stock rose 5.9% premarket
Friday after the company said the U.S. Food and Drug Administration
lifted its clinical hold on studies with Alnylam's hemophilia
treatment, fitusiran. Alnylam and the FDA had previously reached an
agreement to mitigate risk during studies. Alnylam is working with
Sanofi Genzyme, the specialty care unit of Sanofi SA (SAN.FR), on
the treatment. Sanofi shares are down 1% Friday.
(cara.lombardo@wsj.com; @CaraRLombardo)
(END) Dow Jones Newswires
December 15, 2017 07:46 ET (12:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024